Uric acid: a novel mediator and marker of risk in chronic kidney disease?

Curr Opin Nephrol Hypertens. 2009 Nov;18(6):526-30. doi: 10.1097/MNH.0b013e328330d9d0.

Abstract

Purpose of review: To assess the current data suggesting that uric acid-lowering therapy may be useful in the prevention or mitigation of chronic kidney disease (CKD).

Recent findings: Eleven observational studies assessing the potential role of serum uric acid in the prevalence and progression of CKD have been published in the past 2 years. Seven suggest an association, whereas four do not. Recent experimental models and clinical trials have mechanistically linked serum uric acid and hypertension, an established risk factor for CKD.

Summary: Elevated serum uric acid is a marker for decreased renal function, may have a mechanistic role in the incidence and progression of renal functional decline and likely has a causal role in hypertension and vascular disease. Clinical trials are needed to determine whether uric acid-lowering therapy will be effective in preventing CKD.

Publication types

  • Review

MeSH terms

  • Animals
  • Biomarkers / blood
  • Chronic Disease
  • Clinical Trials as Topic
  • Disease Models, Animal
  • Disease Progression
  • Evidence-Based Medicine
  • Humans
  • Hypertension / blood
  • Hypertension / etiology
  • Hyperuricemia / blood
  • Hyperuricemia / complications*
  • Hyperuricemia / drug therapy
  • Hyperuricemia / epidemiology
  • Kidney Diseases / blood
  • Kidney Diseases / epidemiology
  • Kidney Diseases / etiology*
  • Kidney Diseases / prevention & control
  • Predictive Value of Tests
  • Risk Assessment
  • Risk Factors
  • Treatment Outcome
  • Up-Regulation
  • Uric Acid / blood*

Substances

  • Biomarkers
  • Uric Acid